Dataset Information

Protective immunity and safety of a genetically modified influenza virus vaccine.

ABSTRACT: Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. To this aim, one of the most promising approaches consists of generating recombinant viruses harboring partially truncated neuraminidase (NA) segments. To date, all studies have pointed to safety and usefulness of this viral platform. However, some aspects of the inflammatory and immune responses triggered by those recombinant viruses and their safety to immunocompromised hosts remained to be elucidated. In the present study, we generated a recombinant influenza virus harboring a truncated NA segment (vNA-?) and evaluated the innate and inflammatory responses and the safety of this recombinant virus in wild type or knock-out (KO) mice with impaired innate (Myd88 -/-) or acquired (RAG -/-) immune responses. Infection using truncated neuraminidase influenza virus was harmless regarding lung and systemic inflammatory response in wild type mice and was highly attenuated in KO mice. We also demonstrated that vNA-? infection does not induce unbalanced cytokine production that strongly contributes to lung damage in infected mice. In addition, the recombinant influenza virus was able to trigger both local and systemic virus-specific humoral and CD8+ T cellular immune responses which protected immunized mice against the challenge with a lethal dose of homologous A/PR8/34 influenza virus. Taken together, our findings suggest and reinforce the safety of using NA deleted influenza viruses as antigen delivery vectors against human or veterinary pathogens.

SUBMITTER: Barbosa RP

PROVIDER: S-EPMC4057169 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Protective immunity and safety of a genetically modified influenza virus vaccine.

Barbosa Rafael Polidoro Alves RP Salgado Ana Paula Carneiro AP Garcia Cristiana Couto CC Filho Bruno Galvão BG Gonçalves Ana Paula de Faria AP Lima Braulio Henrique Freire BH Lopes Gabriel Augusto Oliveira GA Rachid Milene Alvarenga MA Peixoto Andiara Cristina Cardoso AC de Oliveira Danilo Bretas DB Ataíde Marco Antônio MA Zirke Carla Aparecida CA Cotrim Tatiane Marques TM Costa Érica Azevedo ÉA Almeida Gabriel Magno de Freitas GM Russo Remo Castro RC Gazzinelli Ricardo Tostes RT Machado Alexandre de Magalhães Vieira Ade M

PloS one 20140613 6

Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. To this aim, one of the most promising approaches consists of generating recombinant viruses harboring partially truncated neuraminidase (NA) segments. To date, all studies have pointed to safety and usefulness of this viral platform. However, some aspects of the inflammatory and immune responses triggered by those recombinant viruses and their safety to immunocompromised hosts remained to be eluc ...[more]

PMID: 24927156

Similar Datasets

Project description:BACKGROUND: Influenza virus undergoes constant antigenic evolution, and therefore influenza vaccines must be reformulated each year. Time is necessary to produce a vaccine that is antigenically matched to a pandemic strain. A goal of many research works is to produce universal vaccines that can induce protective immunity to influenza A viruses of various subtypes. Despite intensive studies, the precise mechanisms of heterosubtypic immunity (HSI) remain ambiguous. METHOD: In this study, mice were vaccinated with recombinant virus vaccine (rL H5), in which the hemagglutinin (HA) gene of influenza A/H5N1 virus was inserted into the LaSota Newcastle disease virus (NDV) vaccine strain. Following a challenge with influenza A/H1N1 virus, survival rates and lung index of mice were observed. The antibodies to influenza virus were detected using hemagglutination inhibition (HI). The lung viral loads, lung cytokine levels and the percentages of both IFN-?+CD4+ and IFN-?+CD8+ T cells in spleen were detected using real-time RT-PCR, ELISA and flow cytometry respectively. RESULTS: In comparison with the group of mice given phosphate-buffered saline (PBS), the mice vaccinated with rL H5 showed reductions in lung index and viral replication in the lungs after a challenge with influenza A/H1N1 virus. The antibody titer in group 3 (H1N1-H1N1) was significantly higher than that in other groups which only low levels of antibody were detected. IFN-? levels increased in both group 1 (rL H5-H1N1) and group 2 (rL H5?+?IL-2-H1N1). And the IFN-? level of group 2 was significantly higher than that of group 1. The percentages of both IFN-?+CD4+ and IFN-?+CD8+ T cells in group 1 (rL H5-H1N1) and group 2 (rL H5?+?IL-2-H1N1) increased significantly, as measured by flow cytometry. CONCLUSION: After the mice were vaccinated with rL H5, cross-protective immune response was induced, which was against heterosubtypic influenza A/H1N1 virus. To some extent, cross-protective immune response can be enhanced by IL-2 as an adjuvant. Cellular immune responses may play an important role in HSI against influenza virus.

Dataset Information

Protective immunity and safety of a genetically modified influenza virus vaccine.

Publications

Protective immunity and safety of a genetically modified influenza virus vaccine.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure